Finance ❯ Investments ❯ Risk Management
Volatility Index Investor Awareness Investor Losses Cryptocurrency Risks
Plaintiffs allege Cytokinetics overstated its aficamten approval timeline by submitting an NDA without a REMS after FDA safety discussions.
